© 2022 MJH Life Sciences and CGTLive™. All rights reserved.
© 2022 MJH Life Sciences™ and CGTLive™. All rights reserved.
May 20, 2022
In an interview with CGTLive, study primary investigator Donald Kohn, MD, discussed the safety and efficacy observed in the phase 2 trial.
May 18, 2022
Safety and efficacy data suggest this to be a feasible and clinically meaningful treatment for a patient population with high disease burden.
Data from 2 patients dosed in the Imagine-1 clinical trial were presented in a late breaking session at ASGCT 2022.
May 17, 2022
Study sponsor Pfizer recently announced the launch of a phase 3 trial in patients with Duchenne muscular dystrophy.
May 13, 2022
The investigational therapy is also currently being evaluated in a clinical trial for sickle cell disease.
May 12, 2022
Caribou will present the initial data at the upcoming European Hematology Association (EHA) meeting in June.
Late-breaking interim data were presented at the 14th Myasthenia Gravis Foundation of America (MGFA) International Conference on Myasthenia and Related Disorders.
May 11, 2022
The cell therapy is the first to come out of the company’s proprietary ARC-SparX platform.
May 10, 2022
The trial was set to begin patient dosing in the first half of this year.
May 06, 2022
Investigators presented up to 2 years of post-marketing data on the first-ever gene therapy.